Vol.
36
No.
12
December 27, 2013Dec 27, 2013
Free
TCCL Archive

Phase III Trial Demonstrates Early Docetaxel Combined With ADT Can Extend Survival

TCCL Archive

Phase III Tecemotide Trial Fails OS Endpoint; Second Trial Planned After Subgroup Analysis

TCCL Archive

Multiple Studies Show Benefit of CTL019, A Personalized Therapy, in CLL and ALL

TCCL Archive

Biomarker May Predict Prostate Cancer Metastases

TCCL Archive

Individualized Cancer Vaccines Show 90% Survival at 6 Months

TCCL Archive

Dendritic Cell Vaccine Increases PFS in Phase II Clinical Trial

TCCL Archive

Two Phase II Studies of Ibrutinib Deliver High Response Rates

TCCL Archive

NLST Suggests 18.5 Percent Of LDCT-Detected Cancers Could Be Indolent

TCCL Archive

Study: BRCA2-Negative Women Could Still Have High Risk

TCCL Archive

Velcade Addition Can Improve Graft-Versus-Host Outcomes

TCCL Archive

NCI CTEP Approved Trials For the Month of December

TCCL Archive

FDA Expands Nexavar Indication To Include Thyroid Cancer

Login